Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

February 28, 2028

Study Completion Date

January 31, 2030

Conditions
Mycosis FungoidesSezary SyndromeMycosis Fungoides/Sezary Syndrome
Interventions
DRUG

Tulmimetostat

Patients should take DZR123 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following DZR123 dosing). Each dose of DZR123 should be taken with a glass of water and consumed over as short a time as possible.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

collaborator

Swim Across America

OTHER

collaborator

Daniel E. Corbin Jr. Lymphoma Fund

UNKNOWN

lead

Washington University School of Medicine

OTHER